Literature DB >> 14671638

Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.

H G Drexler1, H Quentmeier, R A F MacLeod.   

Abstract

Human tumor cell lines are powerful tools for investigating basic and applied aspects of cell biology. Leukemia-lymphoma cell lines have been instrumental in the cytogenetic and molecular analysis of recurring chromosome rearrangements, notably translocations and inversions, thus illuminating the pathogenesis of hematological malignancy. Chromosomal translocations targeting the MLL gene at 11q23 have come to represent a paradigm in acute leukemias. These translocations result in the in-frame joining of the MLL gene with a partner gene to generate unique fusion proteins of putatively novel function. More than 30 partner genes that participate with MLL in the more than 60 known 11q23 translocations have been reported. Cell lines provide territory to both explore the detailed structures of 11q23 translocations and investigate the leukemogenic activities of MLL fusion proteins. We review here the leukemia cell lines that have been described to carry 11q23 translocations and MLL fusion genes. Except for the t(10;11)(p12;q23), each of the following relatively frequent 11q23/MLL translocations is represented by one or more cell lines: 16 cell lines with t(4;11)(q21;q23), two cell lines with t(6;11)(q27;q23), seven cell lines with t(9;11)(p22;q23), and eight cell lines with t(11;19)(q23;p13). For each of three rare translocations, one cell line has been reported: t(5;11)(q15;q23), t(11;16)(q23;p13), and t(X;11)(q13;q23). Of these 36 cell lines with 11q23 translocations, 17 have been made available to us; we confirmed the occurrence of the alterations reported in these cell lines at the chromosomal and/or gene level. A second type of MLL gene alteration is the partial tandem duplication (PTD), which occurs in acute myeloid leukemia (AML). We found four AML cell lines with an MLL PTD; one acute lymphoblastic leukemia-derived cell line was reported to show a partial nontandem duplication. Finally, a third rearrangement involves intrachromosomal amplification of the unrearranged MLL gene leading to multiple copies of the gene and (presumably) increased expression. Three cell lines carrying such MLL amplifications have been described. The availability of these cell lines as model systems provides the opportunity to explore the altered expression or functions of MLL genes and their partners in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14671638     DOI: 10.1038/sj.leu.2403236

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  25 in total

1.  Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.

Authors:  Xiaobo Hu; Hui Wei; Laiman Xiang; Oleg Chertov; Alan S Wayne; Tapan K Bera; Ira Pastan
Journal:  Leuk Res       Date:  2013-08-13       Impact factor: 3.156

2.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

3.  The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.

Authors:  Christine M Palermo; Cecily A Bennett; Amanda C Winters; Charles S Hemenway
Journal:  Leuk Res       Date:  2007-09-17       Impact factor: 3.156

4.  Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.

Authors:  Mark C Weir; Sherry T Shu; Ravi K Patel; Sabine Hellwig; Li Chen; Li Tan; Nathanael S Gray; Thomas E Smithgall
Journal:  ACS Chem Biol       Date:  2018-05-30       Impact factor: 5.100

5.  Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.

Authors:  Yuan Wu; Miriam Doepner; Taylor Hojnacki; Zijie Feng; Bryson W Katona; Xin He; Jian Ma; Yan Cao; Luca Busino; Fuxiang Zhou; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

6.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

7.  PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

Authors:  Sarah Picaud; David Da Costa; Angeliki Thanasopoulou; Panagis Filippakopoulos; Paul V Fish; Martin Philpott; Oleg Fedorov; Paul Brennan; Mark E Bunnage; Dafydd R Owen; James E Bradner; Philippe Taniere; Brendan O'Sullivan; Susanne Müller; Juerg Schwaller; Tatjana Stankovic; Stefan Knapp
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

8.  Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.

Authors:  Sonja Röhrs; Wilhelm G Dirks; Claus Meyer; Rolf Marschalek; Michaela Scherr; Robert Slany; Andrew Wallace; Hans G Drexler; Hilmar Quentmeier
Journal:  Mol Cancer       Date:  2009-10-16       Impact factor: 27.401

9.  Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines.

Authors:  Faten Merhi; Jacques Auger; Francine Rendu; Brigitte Bauvois
Journal:  Biologics       Date:  2008-12

10.  Misguided transcriptional elongation causes mixed lineage leukemia.

Authors:  Dorothee Mueller; María-Paz García-Cuéllar; Christian Bach; Sebastian Buhl; Emanuel Maethner; Robert K Slany
Journal:  PLoS Biol       Date:  2009-11-24       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.